1. “My ultrasound says fatty liver but my doctor said it’s nothing. Should I worry?”
Short answer: sometimes yes, sometimes no — and that’s exactly the problem.
“Fatty liver” on ultrasound tells you fat is present, not risk.
What actually determines your future is fibrosis (scarring) — not fat.
I’ve seen patients with:
severe fatty liver → no fibrosis (low risk)
mild fatty liver → advanced fibrosis (high risk)
Ultrasound cannot tell you that difference.
At minimum, you need a simple risk check like FIB-4 or elastography.
If that hasn’t been done, the evaluation is incomplete.
👉 If your report just says “fatty liver” with no risk assessment, you’re missing the most important part.
2. “My ALT is normal now, so my liver is fine, right?”
No. This is one of the biggest myths in liver disease.
ALT is a leak marker, not a damage score.
You can have:
normal ALT
and still have significant fibrosis or even cirrhosis
Especially if you have diabetes, obesity, or metabolic risk factors.
ALT going down doesn’t mean fibrosis reversed.
It often just means inflammation fluctuated.
👉 If your entire follow-up is based on ALT alone, you’re being under-evaluated.
3. “Can fatty liver turn into cirrhosis?”
Yes — but not in everyone.
The real question is: who progresses?
Progression depends on:
fibrosis stage
metabolic risk (diabetes is a big one)
weight trajectory over time
Most people with simple steatosis won’t progress fast.
But once fibrosis starts, the trajectory changes.
👉 The mistake is treating all fatty liver as “same risk.” It’s not.
4. “Do I really need a liver biopsy?”
Not always. In fact, most patients don’t.
Biopsy is useful when:
diagnosis is unclear
non-invasive tests are conflicting
treatment decisions depend on histology
But today, we rely a lot on:
FIB-4
elastography
clinical context
👉 If someone is jumping straight to biopsy without non-invasive stratification, that’s not standard approach anymore.
5. “What’s the best treatment for fatty liver?”
If someone tells you there’s a single “best treatment,” they’re oversimplifying.
Treatment depends on:
fibrosis stage
metabolic profile
weight
comorbidities
That said, across the board:
weight loss remains foundational
metabolic control (especially diabetes) is critical
Medications like GLP-1 based therapies are promising, but not a magic fix.
👉 The goal isn’t just reducing fat — it’s preventing fibrosis progression.
6. “I’m not overweight. How do I have fatty liver?”
Very common, especially in Asian populations.
This is often called lean fatty liver, but that term is misleading.
These patients still have:
insulin resistance
visceral fat
metabolic dysfunction
And yes — they can still develop fibrosis.
👉 Being “not overweight” does not automatically mean “low risk.”
7. “My doctor said just take vitamin E. Is that enough?”
Depends on who you are.
Vitamin E has some evidence in selected non-diabetic patients, but:
it’s not a universal solution
it doesn’t address underlying metabolic drivers
If the entire plan is “take vitamin E and relax,” that’s incomplete.
👉 Treatment without risk stratification is guesswork.
8. “How serious is fatty liver really?”
Most people are asking the wrong question.
It’s not:
“Is fatty liver serious?”
It’s:
“Do I have fibrosis, and if yes, how much?”
Because:
no fibrosis → generally low liver-related risk
advanced fibrosis → completely different prognosis
👉 Same diagnosis, very different outcomes.
9. “Should I be worried about liver cancer with fatty liver?”
Risk is not uniform.
Higher risk if:
cirrhosis is present
long-standing metabolic disease
diabetes
But here’s the nuance:
some patients with fatty liver can develop HCC even without cirrhosis (less common, but real).
👉 If fibrosis stage is unknown, your risk is unknown.
10. “I’ve seen multiple doctors and everyone says something different. What should I do?”
This is more common than people think.
Liver disease — especially fatty liver — sits at the intersection of:
hepatology
endocrinology
general medicine
So you’ll often hear:
“nothing to worry”
“very serious”
“just lose weight”
The issue is not disagreement — it’s lack of structured assessment.
A proper evaluation should answer:
Do you actually have significant fibrosis?
What is driving your disease?
What is the plan to modify risk?
👉 If those three questions aren’t clearly answered, you don’t have a real plan yet.
